BI-4142|cas:2682003-36-5|西域试剂

BI-4142,98.39%

产品编号：Bellancom-150024| CAS NO：2682003-36-5| 分子式：C₂₈H₂₇N₉O₂| 分子量：521.57

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-150024		￥6800.00	杭州北京（现货）
Bellancom-150024		￥10900.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

BI-4142

产品介绍

BI-4142 是一种有效的、高选择性的、具有口服活性的 HER2 抑制剂，IC₅₀ 值为 5 nM。

生物活性

BI-4142 is a potent, highly selective and orally active HER2 inhibitor with an IC₅₀ of 5 nM.

体外研究

BI-4142 shows inhibition with IC₅₀ values of 10 nM, 18 nM, 270 nM and 2400 nM against HEK HER2^YVMA, Ba/F3 HER2^YVMA, HEK EGFR^WT and Ba/F3 EGFR^WT, respectively.
BI-4142 (1 nM-5 μM, 72 h or 96 h) shows antiproliferative activity against tumor cells.
BI-4142 displays good permeability and no PgP-mediated efflux liability in the CaCo-2 assay.
BI-4142 inhibits HER2-dependent cell lines and inhibits downstream signaling.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	NCI-H2170 HER2^WT, NCI-H2170 HER2^YVMA, A431 EGFR^WT, Ba/F3 HER2^YVMA, Ba/F3 HER2^YVMA,S783C, Ba/F3 EGFR^WT and Ba/F3 EGFR^C775S cells
Concentration:	1 nM-5 μM
Incubation Time:	72 h or 96 h
Result:	Showed antiproliferative effect with IC₅₀ values of 16 nM, 82 nM, >5 µM, 4 nM, 24 nM, 718 nM and 43 nM against NCI-H2170 HER2^WT, NCI-H2170 HER2^YVMA, A431 EGFR^WT, Ba/F3 HER2^YVMA, Ba/F3 HER2^YVMA,S783C, Ba/F3 EGFR^WT and Ba/F3 EGFR^C775S, respectively.

体内研究
(In Vivo)

BI-4142 (0-100 mg/kg; p.o.; twice per day for 40 days) inhibits tumor growth and inhibits oncogenic signaling.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NMRI-Foxn1nu mice, PC-9 HER2^YVMA xenograft model
Dosage:	3, 10, 30 and 100 mg/kg
Administration:	Oral administration, twice per day for 40 days
Result:	Resulted in tumor regressions in a dose-dependent manner (113%, 126%, 153% and 166% tumor growth inhibition at 3, 10, 30 and 100 mg/kg, respectively).

Animal Model:

BomTac:NMRI Foxn1nu mice

Dosage:

1 mg/kg or 10mg/kg and 100 mg/kg

Administration:

IV for 1 mg/kg, PO for 10mg/kg and 100 mg/kg (Pharmacokinetic Analysis)

Result:

In vivo mouse PK data for BI-4142

Compound	Dose iv/po (mg/kg)	tmax (h)	C_max (nM)	AUD (h•nM)	Plasma CL (mL/min/kg)	% F
	i.v., 1mg/kg	n/a	n/a	3,280	9.69	n/a
BI-4142	p.o., 10 mg/kg	0.83	8,600	23,200	n/a	71
	p.o., 100 mg/kg	0.67	36,400	196,000	n/a	60

体内研究

BI-4142 (0-100 mg/kg; p.o.; twice per day for 40 days) inhibits tumor growth and inhibits oncogenic signaling.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NMRI-Foxn1nu mice, PC-9 HER2^YVMA xenograft model
Dosage:	3, 10, 30 and 100 mg/kg
Administration:	Oral administration, twice per day for 40 days
Result:	Resulted in tumor regressions in a dose-dependent manner (113%, 126%, 153% and 166% tumor growth inhibition at 3, 10, 30 and 100 mg/kg, respectively).

Animal Model:

BomTac:NMRI Foxn1nu mice

Dosage:

1 mg/kg or 10mg/kg and 100 mg/kg

Administration:

IV for 1 mg/kg, PO for 10mg/kg and 100 mg/kg (Pharmacokinetic Analysis)

Result:

In vivo mouse PK data for BI-4142

Compound	Dose iv/po (mg/kg)	tmax (h)	C_max (nM)	AUD (h•nM)	Plasma CL (mL/min/kg)	% F
	i.v., 1mg/kg	n/a	n/a	3,280	9.69	n/a
BI-4142	p.o., 10 mg/kg	0.83	8,600	23,200	n/a	71
	p.o., 100 mg/kg	0.67	36,400	196,000	n/a	60

体内研究

BI-4142 (0-100 mg/kg; p.o.; twice per day for 40 days) inhibits tumor growth and inhibits oncogenic signaling.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NMRI-Foxn1nu mice, PC-9 HER2^YVMA xenograft model
Dosage:	3, 10, 30 and 100 mg/kg
Administration:	Oral administration, twice per day for 40 days
Result:	Resulted in tumor regressions in a dose-dependent manner (113%, 126%, 153% and 166% tumor growth inhibition at 3, 10, 30 and 100 mg/kg, respectively).

Animal Model:

BomTac:NMRI Foxn1nu mice

Dosage:

1 mg/kg or 10mg/kg and 100 mg/kg

Administration:

IV for 1 mg/kg, PO for 10mg/kg and 100 mg/kg (Pharmacokinetic Analysis)

Result:

In vivo mouse PK data for BI-4142

Compound	Dose iv/po (mg/kg)	tmax (h)	C_max (nM)	AUD (h•nM)	Plasma CL (mL/min/kg)	% F
	i.v., 1mg/kg	n/a	n/a	3,280	9.69	n/a
BI-4142	p.o., 10 mg/kg	0.83	8,600	23,200	n/a	71
	p.o., 100 mg/kg	0.67	36,400	196,000	n/a	60

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (191.73 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.9173 mL	9.5864 mL	19.1729 mL
5 mM	0.3835 mL	1.9173 mL	3.8346 mL
10 mM	0.1917 mL	0.9586 mL	1.9173 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

参考文献